
LNP biotech looks to go beyond the liver, raising $25M in seed money to move forward
Hopewell Therapeutics announced $25 million in seed funding on Wednesday, with the Boston-area biotech looking to make the next breakthrough in delivering medicines beyond the liver.
The seed round was backed by a number of venture capital firms, including 5Y Capital and Mass Ave Capital, and will be used to expand Hopewell’s internal lab capabilities and grow its lipid nanoparticle library, according to CEO Louis Brenner. The company’s also looking for external partnerships with companies focused on cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.